Loading...
•
Sep 30
TELA Bio Q3 2025 Earnings Report
TELA Bio reported a net loss of $8.6 million in Q3 2025 despite revenue growth driven by international expansion and product launches.
Key Takeaways
TELA Bio saw a 9% revenue increase in Q3 2025, supported by international sales and new product configurations. While gross profit improved, the company continued to operate at a loss. Operating expenses decreased year-over-year, and the company ended the quarter with nearly $30 million in cash.
Revenue rose to $20.7 million, up 9% year-over-year.
Gross profit reached $14.0 million, with a 67.5% gross margin.
Net loss was $8.6 million, showing an improvement over the $10.4 million loss last year.
Cash and cash equivalents totaled $29.7 million at the end of the quarter.
TELA Bio
TELA Bio
Forward Guidance
TELA Bio expects full-year 2025 revenue growth of at least 16%, supported by product portfolio enhancements and sales expansion.
Positive Outlook
- Revenue guidance raised to at least 16% growth for FY2025
- Credit facility up to $70 million secured to strengthen liquidity
- Completed hiring goals for U.S. sales force expansion
- Continued international growth momentum
- New product configurations positively impacted sales
Challenges Ahead
- Net loss continued in Q3 2025 despite improved operating performance
- Gross margin slightly decreased from the prior year
- Revenue growth partially offset by pricing pressure due to product mix
- Total assets declined significantly year-over-year
- No specific breakdown of revenue contribution from new segments or regions